13 Aug 2014
The Food and Drug Administration has approved Invokamet, a fixed-dose combination of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, and metformin, for type 2 diabetes. The drug will marketed in the USA by Janssen Pharmaceuticals.
Call for nominations for Awards Committee Chair
30 Oct 2024
James M Tanner Award - 2025 nominations open
30 Oct 2024
Would you like to host the BSPED annual meeting?
21 Oct 2024